Zika purified inactivated vaccine

Zika purified inactivated vaccine (ZPIV) is a whole-virus, formalin-inactivated Zika virus vaccine candidate developed by the Walter Reed Army Institute of Research (WRAIR) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and Beth Israel Deaconess Medical Center (BIDMC). It is based on a chromatographic-column-purified, formalin-inactivated Puerto Rico strain of Zika virus (PRVABC59) and is formulated with an aluminum hydroxide (alum) adjuvant. ZPIV is designed to elicit robust neutralizing antibodies against the Zika virus envelope protein to prevent Zika virus infection and its associated complications, such as Congenital Zika Syndrome (CZS) and Guillain-Barré syndrome. The vaccine has completed Phase I clinical trials in healthy adults, demonstrating safety and immunogenicity, and has shown protective efficacy in preclinical animal models of pregnancy.

Other names

Zika purified inactivated virus vaccineZika purified inactivated whole virus vaccineZika virus purified inactivated vaccineZPIV vaccine